非小细胞肺癌中CDK4Ⅰ/P16的表达及与淋巴转移关系的研究

CDK4I/P16 expression and it`s correlation with metastaticcancer of lymph node in humannon-small cell cancer.

为研究ＣＤＫ４Ⅰ／Ｐ１６与非小细胞肺癌的发生及发展的关系，应用免疫组化ＬＳＡＢ法研究了８３例肺癌手术标本中ＣＤＫ４Ⅰ蛋白的表达。结果显示，ＣＤＫ４Ⅰ蛋白表达总的平均阳性率为６５．９３％。Ｐ１６蛋白表达与肺癌的临床分期，组织学分类、肺癌原发部位、患者的年龄及有淋巴结转移的原发灶与无淋巴结转移的原发灶之间比较无显著差异（Ｐ＞０．０５），中一高分化的肺癌（７７．９５％）与低分化的肺癌（５３．０５％）之间有显著差异（Ｐ＜０．０１）；肺癌的原发灶（６４．１６％）与相应转移灶（淋巴灶）（５３．６６％）之间有显著差异（Ｐ＜０．０１）。肿瘤大小Ｔ１＋Ｔ２（６８．９０％）与Ｔ３＋Ｔ４（６０．８３％）之间差异显著（Ｐ＜０．０５）。本研究结果表明ＣＤＫ４Ⅰ蛋白检测可以作为人非小细胞肺癌的抑制基因，并可能是肺癌术后预后的重要指标之一。

Using Labelled streptavidin-biotin(LSAB) method,we examined the expression of cyclin-dependent kinases 4 inhibitor/P16(CDK4Ⅰ)in 83 cases of human non-small cell lung cancer,the average rate of P16 protein positive expression was 65.93%,The positive expression werw higher in moderate-well differentiation of tumor cell(77.95%) than in poorly differentiation (53.0.%)(P<0.01),higher incidnce of P16 positive expression were found in primary lesions(64.16%)than in metastatc lesions (the metastatic cancer of lymph node)(53.66%).There were also sognificant differences between T1+T2(68.90%)in tumor size and T3+T4(60.83%)in.There were not signficant differentiation between the clinical stage,between the pathological types of the carcinoma,and between primary sites,between metastatic status of lymph node and between patients,ages(P>0.05).The results suggest that CDK4Ⅰ/P16 gene may be the suppressor gene in human non-small cell lung cancer and a Key index judging prognsis of postoperative patients of lung cancer. 